Stories
The New York-listed pharmaceutical giant is involved with a judicial review of its tax affairs one year after a last-ditch Budget Day stamp duty change added hundreds of millions to the cost of its Allergan acquisition.
Last May, the High Court cleared the scheme of arrangement entered by AbbVie to acquire Irish-headquartered Allergan. This week, solicitors from Dublin law firm Matheson were back in the Four Courts – this time in relation to a judicial review of the taxation of the US pharmaceutical multinational in Ireland. The group’s Chicago-headquartered parent, AbbVie Inc, was listed in proceedings with the Revenue Commissioners on Wednesday. The legal action follows a year-long battle with the tax authority over the acquisition of Allergan, which AbbVie agreed in June 2019. The transaction closed last summer when Allergan cancelled its shares and issued…
Don’t miss out on what is going on with our daily unique stories from our team of skilled journalists and insightful commentators. Members of The Currency get full access to over 1,500 exclusive interviews, investigations, and analysis, plus over 75 podcasts. Annual membership is just €200 for the first year, a saving of €100. Or try The Currency for the first month for just €5, a saving of €20. Cancel at any time. To become a member today click here.
Join The Currency
Special offer: Full annual membership for just €200.
